查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867192

DNA修復药物市场按药物类别、作用机制、适应症、给药途径和最终用户划分－2025-2032年全球预测

DNA Repair Drugs Market by Drug Class, Mechanism Of Action, Indication, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，DNA 修復药物市场将成长至 163.1 亿美元，复合年增长率为 7.44%。

关键市场统计数据
基准年 2024 91.8亿美元
预计年份：2025年 98.7亿美元
预测年份 2032 163.1亿美元
复合年增长率 (%) 7.44%

全面概述定义现代肿瘤学中DNA修復疗法的科学进展、法规环境和商业性需求。

DNA修復疗法领域融合了分子生物学、精准肿瘤学和新型药物疗法，正在重新定义多种肿瘤的治疗方法。近年来，随着对肿瘤基因组学和合成致死机制理解的不断深入，靶向DNA损害反应路径的治疗方法已从学术研究转变为特定适应症的临床常用疗法。该领域目前涵盖了已开发的药物类别以及旨在利用癌细胞新发现的弱点的新兴抑制剂。

基因组精准医疗、适应性检测和联合疗法如何重塑DNA修復治疗领域的研发重点和商业模式

DNA修復疗法生态系统正在经历一场变革，而这场变革正在改变研发重点、临床试验设计和商业模式。基因组分析和生物标记检验的进步迫使研发人员设计具有分子选择性和适应性的试验，从而能够快速识别有效患者，同时减少无效患者的暴露。同时，将DNA修復抑制剂与免疫疗法、标靶治疗或传统细胞毒性药物合併使用的策略，已从探索性方案发展为系统性的开发路径，这反映出策略性重心正向多模态疗法转变。

2025年关税趋势将如何影响全球药品供应链、研发时间表以及DNA修復疗法的获取策略

政策变化，包括已宣布或将于2025年实施的关税，使跨境医药原料和成品供应链再次受到关注。由于许多DNA修復疗法依赖特殊的活性药物原料药、复杂的化学合成以及进口的实验室耗材，关税带来的成本压力可能会影响生产经济效益和临床供应物流。为此，各公司正在重新评估供应商多样性，尽可能将关键生产环节迁回国内，并协商长期采购协议以降低价格波动。

细緻入微的细分市场挑战表明，药物类别、作用机制、适应症、给药途径和最终用户趋势如何共同塑造了不同的研发和商业化策略。

细分市场层面的洞察揭示了不同作用机制、适应症、给药途径和最终用户群所对应的独特研发路径和商业性考量，这些因素共同决定了投资重点。按药物类别划分，竞争格局和临床环境涵盖了ATM抑制剂、Atr抑制剂、 DNA甲基转移酵素抑制剂、HDAC抑制剂和PARP抑制剂。在这些类别中， DNA甲基转移酵素抑制剂又可分为已上市药物和在研药物，而PARP抑制剂则呈现出多层次的市场结构，包括品牌药、非专利和在研药物，这影响着定价和市场定位策略。这种多样性要求在药物生命週期的各个阶段采取差异化策略：已上市学名药需要扩大市场准入范围并采取以销量为导向的策略。

基于区域监管、报销和基础设施实际情况的策略差异化将决定临床开发重点和市场进入策略。

区域趋势对DNA修復疗法研发、监管沟通和商业化方面的策略决策具有重要意义。在美洲，人们尤其重视那些强调快速监管沟通、支付方证据产生和生物标记主导适应症的推广路径。临床试验网络和肿瘤联盟为后期评估和真实世界证据的收集提供了强大的支持。欧洲、中东和非洲（EMEA）地区的市场环境则更为复杂，监管协调、报销差异和医疗基础设施的不同要求企业制定个人化的上市计划和差异化的定价策略。製造商通常会根据卫生技术评估（HTA）框架和集中式/分散式报销机制，优先选择该地区的国家进行早期上市。

领先开发商采取的企业策略包括：建立伙伴关係以加速产品推广、整合诊断功能、建立稳健的供应链以及基于证据的商业化。

DNA修復疗法领域的主要企业展现出通用的策略行为：建立合作伙伴关係以拓展联合治疗，投资伴随诊断研发以支持精准的患者筛选，以及进行有针对性的併购和许可活动以强化互补资产。大型製药企业正在扩大与生物技术公司的合作，以加速转化科学发展并获取新型化学类型和专有生物标记平台。同时，灵活的生物技术公司正利用早期概念验证数据来协商共同开发契约并资金筹措临床实验试验，从而建立一个以互补能力和风险共用为核心的生态系统，推动发展。

明确且可操作的经营团队重点，以整合生物标记主导的证据、稳健的业务运营以及DNA修復项目的有针对性的商业化。

产业领导者应优先考虑一系列切实可行的倡议，将科学潜力转化为持续的商业性成功。首先，将生物标记策略和卫生经济学纳入早期研发计划，确保临床试验结果符合支付方预期和临床决策。这将有助于申办方缩短产品上市时间，并提升产品上市时的价值定位。其次，寻求策略联盟，将互补的作用机製或治疗方式结合，以增强联合治疗的实证基础，并分散整个研发组合的风险。

一项结合专家访谈、全面二手资料和三角验证分析技术的稳健的多方法研究设计，确保了研究的有效性和透明度。

为确保洞察的广度和深度，本研究采用结构化的多方法整合数据，结合了第一手资料和第二手资料。第一手资料包括对肿瘤领域关键高管、大型和小型生物製药公司高管、监管专家和市场进入负责人的访谈，以深入了解临床开发、监管预期和商业化挑战。第二手资料涵盖同行评审文献、临床试验註册信息、监管文件、专利概况和公司披露信息，以验证研究结果并检验战略趋势。

总之，我们强调，必须将基于机制的创新、证据生成和营运韧性结合起来，才能实现持续的临床和商业性影响。

总之，DNA修復疗法在肿瘤学领域中占据着至关重要且快速发展的细分市场，科学进步、临床检验和商业性可行性必须协同作用，才能真正造福患者。该领域的未来不仅取决于机制创新，还取决于整合生物标记、建立稳健的供应和生产策略以及产生实现广泛应用所需的卫生经济学证据的组织能力。策略伙伴关係和适应性试验设计将迅速将有前景的机制转化为永续的临床应用方案，而在地化的上市计划将决定患者接受治疗的速度和范围。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新兴的PARP抑制剂联合治疗有望克服BRCA突变癌症的抗药性
  • 基于 CRISPR 的标靶 DNA 修復治疗方法在罕见遗传疾病治疗中的进展
  • 开发针对DNA损害反应激酶ATM和ATR的小分子抑制剂
  • 扩大精准肿瘤学研发管线，聚焦合成致死策略
  • 将基于生物标记的患者选择纳入DNA修復调节剂的临床试验
  • 人工智慧驱动的新型DNA修復候选药物筛检平台投资趋势

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. DNA修復药物市场依药物类别划分

  • ATM抑制剂
  • ATR抑制剂
  • DNA甲基转移酵素酶抑制剂
    • 已发布
    • 管道
  • HDAC抑制剂
  • PARP抑制剂
    • 品牌产品
    • 学名药
    • 管道

9. DNA修復药物市场依作用机转划分

  • 单株抗体
  • 胜肽
  • 低分子化合物
    • ATM抑制剂
    • ATR抑制剂
    • DNA甲基转移酵素酶抑制剂
    • HDAC抑制剂
    • PARP抑制剂

第十章 DNA修復药物市场依适应症划分

  • 乳癌
    • HER2阳性
    • 荷尔蒙受体阳性
    • 三重否定
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第十一章 DNA修復药物市场依给药途径划分

  • 静脉注射
  • 口服
  • 皮下注射

第十二章 DNA修復药物市场（依最终用户划分）

  • 医院
  • 药局
  • 专科诊所

第十三章 DNA修復药物市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 DNA修復药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国DNA修復药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Clovis Oncology, Inc.
    • Pfizer Inc.
Product Code: MRR-99555D550531

The DNA Repair Drugs Market is projected to grow by USD 16.31 billion at a CAGR of 7.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.18 billion
Estimated Year [2025] USD 9.87 billion
Forecast Year [2032] USD 16.31 billion
CAGR (%) 7.44%

Comprehensive orientation to the scientific advancements, regulatory context, and commercial imperatives defining DNA repair therapeutics in contemporary oncology

The DNA repair therapeutics landscape represents a convergence of molecular biology, precision oncology, and novel drug modalities that together are redefining treatment approaches for multiple tumor types. In recent years, therapies targeting DNA damage response pathways have moved from academic curiosity to clinical staples in certain indications, driven by a deeper mechanistic understanding of tumor genomics and synthetic lethality. The field now spans established classes of agents alongside emergent inhibitors that seek to exploit newly discovered vulnerabilities in cancer cells.

This introduction synthesizes the state of play for stakeholders who require a concise, authoritative orientation. It outlines the technological drivers, regulatory context, and commercial considerations shaping development priorities. By placing clinical innovation in the context of operational realities-supply chain resilience, payer engagement, and biomarker deployment-this section equips decision-makers with the baseline perspective needed to interpret subsequent, more granular analyses. Transitioning from scientific promise to routine clinical integration remains the central theme, highlighting the interplay among translational research, regulatory pathways, and commercial strategy.

How genomic precision, adaptive trials, and combination strategies are collectively reshaping development priorities and commercial models across DNA repair therapeutics

The DNA repair therapeutics ecosystem is experiencing transformative shifts that are altering R&D priorities, clinical trial design, and commercial models. Advances in genomic profiling and biomarker validation have compelled developers to design trials that are both molecularly selective and adaptive, enabling faster identification of responders while reducing exposure for non-responders. Concurrently, combination strategies that pair DNA repair inhibitors with immunotherapies, targeted agents, or conventional cytotoxics have matured from exploratory regimens into structured development paths, reflecting a strategic recalibration toward multi-modal approaches.

On the technological front, the rise of next-generation sequencing and liquid biopsy platforms has increased the feasibility of real-time patient selection and monitoring, thereby tightening the feedback loop between clinical outcomes and molecular hypotheses. From a commercial standpoint, payers and health systems are increasingly demanding demonstrable value through biomarker-defined benefit, driving sponsors to integrate health economics and outcomes research earlier in development. As a result of these intersecting forces, the landscape is evolving from single-agent, indication-focused pursuits to more nuanced, mechanism-driven portfolios that emphasize precision, combination potential, and sustainable access models.

Implications of 2025 tariff dynamics on global pharmaceutical supply chains, development timelines, and access strategies for DNA repair therapeutics

Policy shifts involving tariff measures announced or implemented in 2025 have generated renewed attention to cross-border supply chains for pharmaceutical ingredients and finished products. For DNA repair therapeutics-many of which rely on specialized active pharmaceutical ingredients, complex chemical synthesis, and imported laboratory consumables-tariff-driven cost pressures can affect manufacturing economics and the logistics of clinical supply. In response, companies are reassessing supplier diversity, onshoring critical production steps where feasible, and negotiating longer-term procurement contracts to mitigate price volatility.

Beyond immediate cost implications, tariffs interact with regulatory and commercial levers. Higher input costs can prompt adjustments to portfolio prioritization, delaying lower-priority indications or pipeline candidates that require extensive global distribution channels. In parallel, procurement and tender practices among hospitals and health systems may shift toward domestic suppliers or incumbent therapies with established supply resilience, potentially complicating market access for newer entrants dependent on international manufacturing footprints. To navigate this environment, organizations are increasing visibility into tiered supplier risk, enhancing inventory forecasting for pivotal trials, and accelerating localization strategies for manufacturing and quality control infrastructure to sustain development timelines and patient access.

Nuanced segment-driven imperatives showing how drug class, mechanism, indication, route, and end-user dynamics combine to shape distinct development and commercialization strategies

Segment-level insights reveal distinct development pathways and commercial considerations across mechanisms, indications, routes, and end users that collectively define investment priorities. By drug class, the competitive and clinical landscape spans Atm inhibitors, Atr inhibitors, Dna methyltransferase inhibitors, Hdac inhibitors, and Parp inhibitors; within these groups, Dna methyltransferase inhibitors are bifurcated between launched agents and those in the pipeline, while Parp inhibitors present a layered market of branded, generic, and pipeline entrants that influence pricing and positioning strategies. This heterogeneity necessitates differentiated lifecycle approaches: launched agents require label expansion and real-world evidence generation, pipeline candidates demand translational validation and strategic partnerships, and generics call for access and volume-driven tactics.

Considering mechanism of action, therapies based on monoclonal antibodies, peptides, and small molecules exhibit divergent development and commercialization profiles, with small molecules further subdivided into Atm, Atr, Dna methyltransferase, Hdac, and Parp inhibitor chemotypes. The modality influences dosing paradigms, manufacturing complexity, and intellectual property strategies. Indication-focused segmentation highlights breast, ovarian, pancreatic, and prostate cancers as primary therapeutic arenas, with breast cancer further resolved into Her2 positive, hormone receptor positive, and triple-negative subtypes; such granularity drives unique biomarker needs and payer narratives for each subgroup. Route of administration-intravenous, oral, and subcutaneous-affects patient adherence, clinic resource utilization, and homecare opportunities, while end user segmentation across hospitals, pharmacies, and specialty clinics shapes distribution strategies and commercial engagement models. Taken together, these intersecting segments prescribe distinct development roadmaps, go-to-market architectures, and evidence-generation priorities that innovators must reconcile when allocating finite resources.

Regional strategic differentiation across regulatory, reimbursement, and infrastructure realities that determine clinical development priorities and market access approaches

Regional dynamics materially influence strategic decision-making across development, regulatory engagement, and commercialization for DNA repair therapeutics. In the Americas, there is a pronounced emphasis on rapid regulatory engagement, payer evidence generation, and adoption pathways that favor biomarker-driven indications; clinical trial networks and oncology consortia provide a robust environment for late-stage evaluation and real-world evidence capture. Europe, Middle East & Africa present a more heterogeneous landscape where regulatory harmonization, reimbursement diversity, and variable healthcare infrastructure necessitate tailored market entry plans and differentiated pricing strategies. Manufacturers often prioritize countries within the region for early launches based on HTA frameworks and centralized or decentralized reimbursement mechanisms.

Asia-Pacific demonstrates a mix of rapid innovation adoption in select markets and infrastructure-driven constraints in others. Several countries in Asia-Pacific prioritize domestic manufacturing and local clinical data, prompting sponsors to adapt trial designs and commercial models to meet local requirements. Cross-region considerations-such as regional clinical trial enrollment strategies, supply chain routing, and localized evidence generation-play a pivotal role in shaping program timelines and access. Ultimately, regional strategies must balance the imperative for global coordination with the need to localize regulatory, clinical, and commercial approaches to achieve sustainable patient access.

Corporate strategies observed among leading developers focusing on partnerships, diagnostics integration, resilient supply chains, and evidence-driven commercialization to accelerate adoption

Leading companies in the DNA repair therapeutics domain are demonstrating a common set of strategic behaviors: forging collaborative partnerships to expand combination regimens, investing in companion diagnostic development to support precise patient selection, and deploying targeted M&A or licensing activity to shore up complementary assets. Large pharmaceutical firms are increasingly partnering with biotechs to accelerate translational science and to gain access to novel chemotypes or unique biomarker platforms. At the same time, nimble biotechnology companies are leveraging early proof-of-concept data to negotiate co-development deals or to secure capital for pivotal trials, demonstrating an ecosystem where complementary capabilities and shared risk are central to progress.

Commercially, companies are aligning external affairs, medical affairs, and market access functions earlier in development to ensure that evidence generation addresses payer needs. Supply chain resilience and localized manufacturing are emerging as strategic priorities for firms seeking to protect launch timelines against geopolitical and tariff-related headwinds. Finally, the competitive landscape is prompting companies to differentiate through real-world evidence initiatives, patient support programs, and direct engagement with specialist centers to accelerate adoption where clinical benefit is clearest. These tactics collectively reflect a shift toward more integrated, evidence-driven commercialization strategies across incumbent and emerging players alike.

Clear, implementable priorities for leadership to align biomarker-driven evidence, resilient operations, and targeted commercialization for DNA repair programs

Industry leaders should prioritize a set of actionable initiatives that translate scientific promise into durable commercial success. First, integrate biomarker strategies and health economics into early development plans so that trials generate outcomes aligned with payer expectations and clinical decision-making. By doing so, sponsors can reduce time-to-access hurdles and improve value positioning at launch. Second, pursue strategic collaborations that pair complementary mechanisms or modalities to strengthen rationale for combination regimens and to diversify risk across development portfolios.

Third, build supply chain resilience by diversifying API sources, investing in regional manufacturing capacity where justified, and establishing robust inventory planning for pivotal trials. These actions mitigate exposure to tariff shocks and logistical disruptions. Fourth, invest in companion diagnostic partnerships and real-world evidence capture to substantiate effectiveness and to support label expansion efforts. Lastly, tailor regional go-to-market approaches that account for local regulatory, reimbursement, and infrastructure nuances, and deploy targeted stakeholder engagement to accelerate guideline adoption and clinician uptake. Executing these initiatives in a coordinated fashion will improve the likelihood that promising therapeutics transition to widely accessible standards of care.

Robust multi-method research design combining expert primary interviews, comprehensive secondary sources, and triangulated analytical techniques to ensure validity and transparency

This research synthesizes data from a structured multi-method approach combining primary and secondary sources to ensure breadth and depth of insight. Primary research included interviews with key opinion leaders in oncology, executives from small and large biopharmaceutical companies, regulatory specialists, and market access professionals to capture nuanced perspectives on clinical development, regulatory expectations, and commercialization challenges. Secondary research encompassed peer-reviewed literature, clinical trial registries, regulatory filings, patent landscapes, and company disclosures to triangulate findings and validate strategic trends.

Analytical techniques applied include pipeline mapping, competitive landscaping, and scenario-based impact assessment to understand how policy, clinical, and commercial variables interact. Quality controls included source triangulation, expert validation workshops, and a documented audit trail for critical assumptions. The methodology acknowledges limitations related to evolving clinical data and policy changes, and it therefore highlights where findings are most sensitive to new trial outcomes or regulatory developments. Where possible, the analysis emphasizes reproducible methods and transparent rationale so that stakeholders can adapt the approach to their specific decision-making needs.

Concluding synthesis emphasizing the imperative to align mechanistic innovation, evidence generation, and operational resilience to achieve durable clinical and commercial impact

In conclusion, DNA repair therapeutics occupy a pivotal and rapidly evolving niche within oncology where scientific advances, clinical validation, and commercial execution must align to realize patient benefit. The sector's future will be defined not only by mechanistic innovation but also by the ability of organizations to integrate biomarkers, build resilient supply and manufacturing strategies, and generate the health-economic evidence required for broad access. Strategic partnerships and adaptive trial designs will accelerate the translation of promising mechanisms into durable clinical options, while regionally tailored launch plans will determine the speed and extent of patient uptake.

Ultimately, success in this space demands coordinated action across R&D, regulatory affairs, supply chain, and commercial functions. Stakeholders who proactively address evidence generation, payer alignment, and operational resilience will be best positioned to transform scientific opportunity into sustainable therapeutic impact for patients across the major oncology indications served by DNA repair strategies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of PARP inhibitor combinations to overcome resistance in BRCA-mutated cancers
  • 5.2. Advances in CRISPR-based targeted DNA repair therapeutics for rare genetic disorders
  • 5.3. Development of small molecule inhibitors targeting DNA damage response kinases ATM and ATR
  • 5.4. Growth of precision oncology pipelines focusing on synthetic lethality strategies
  • 5.5. Integration of biomarker-driven patient selection in clinical trials for DNA repair modulators
  • 5.6. Investment trends in AI-driven screening platforms for novel DNA repair drug candidates

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Repair Drugs Market, by Drug Class

  • 8.1. Atm Inhibitors
  • 8.2. Atr Inhibitors
  • 8.3. Dna Methyltransferase Inhibitors
    • 8.3.1. Launched
    • 8.3.2. Pipeline
  • 8.4. Hdac Inhibitors
  • 8.5. Parp Inhibitors
    • 8.5.1. Branded
    • 8.5.2. Generic
    • 8.5.3. Pipeline

9. DNA Repair Drugs Market, by Mechanism Of Action

  • 9.1. Monoclonal Antibodies
  • 9.2. Peptides
  • 9.3. Small Molecules
    • 9.3.1. Atm Inhibitors
    • 9.3.2. Atr Inhibitors
    • 9.3.3. Dna Methyltransferase Inhibitors
    • 9.3.4. Hdac Inhibitors
    • 9.3.5. Parp Inhibitors

10. DNA Repair Drugs Market, by Indication

  • 10.1. Breast Cancer
    • 10.1.1. Her2 Positive
    • 10.1.2. Hormone Receptor Positive
    • 10.1.3. Triple Negative
  • 10.2. Ovarian Cancer
  • 10.3. Pancreatic Cancer
  • 10.4. Prostate Cancer

11. DNA Repair Drugs Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. DNA Repair Drugs Market, by End User

  • 12.1. Hospitals
  • 12.2. Pharmacies
  • 12.3. Specialty Clinics

13. DNA Repair Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. DNA Repair Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. DNA Repair Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AstraZeneca PLC
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. GlaxoSmithKline plc
    • 16.3.4. Clovis Oncology, Inc.
    • 16.3.5. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DNA REPAIR DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DNA REPAIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DNA REPAIR DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST DNA RE